Clovis Oncology Inc. (NASDAQ:CLVS)’s share price was down 2.4% during mid-day trading on Friday . The stock traded as low as $14.16 and last traded at $14.19, with a volume of 271,395 shares changing hands. The stock had previously closed at $14.54.

Several equities analysts recently issued reports on CLVS shares. Leerink Swann boosted their price target on Clovis Oncology from $104.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, March 28th. Piper Jaffray Cos. restated a “hold” rating and set a $18.00 price target on shares of Clovis Oncology in a research note on Tuesday, April 5th. WallachBeth Capital lowered their price target on Clovis Oncology from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Monday, May 9th. Credit Suisse Group AG lowered Clovis Oncology from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $32.00 to $14.00 in a research note on Wednesday, April 13th. Finally, Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $29.25.

The firm’s market cap is $544.68 million. The company has a 50-day moving average of $14.29 and a 200 day moving average of $17.34.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.39) by $0.22. During the same quarter last year, the company earned ($1.86) earnings per share. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts anticipate that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of CLVS. Trexquant Investment LP purchased a new stake in shares of Clovis Oncology during the fourth quarter valued at about $3,170,000. California State Teachers Retirement System increased its stake in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 889 shares during the period. ProShare Advisors LLC increased its stake in shares of Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock valued at $1,265,000 after buying an additional 3,125 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 1,880 shares during the period.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.